<DOC>
	<DOCNO>NCT00323882</DOCNO>
	<brief_summary>Multicenter study patient metastatic hormone refractory prostate cancer ( HRPC ) , previous chemotherapy immunotherapy treatment , receive MDX-010 every 3 week 4 dos ( 12 week total duration induction ) . MDX-010 administered escalate dosage level 3 , 5 , 10 mg/kg/dose infusion . At least 6 patient enrolled dosage level . Patients tolerate responded treatment stable disease 3 month longer subsequently progress follow phase study option receive additional treatment MDX-010 , 4 cycle . Patients follow study response 2 year follow survival status 5 year enrollment .</brief_summary>
	<brief_title>Study MDX-010 Patients With Metastatic Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologic diagnosis adenocarcinoma prostate Metastatic prostate cancer ( positive bone scan measurable disease ) Total testosterone less 50 ng/dL , except patient prior orchiectomy , testosterone need measure . Patients receive antiandrogen part primary androgen ablation must demonstrate disease progression follow discontinuation antiandrogen completion washout period observe disease progression . Patients must stop use herbal product know decrease PSA level ( eg. , saw palmetto PCSPES ) systemic topical corticosteroid least 4 week prior screen . Progressive disease must document discontinuation product . Progressive disease androgen deprivation ( hormone therapy ) . For patient measurable disease , progression define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . For patient progression , without measurable disease , positive bone scan elevate PSA require . Patients receive bisphosphate therapy must stable dos least 4 week stable symptom prior enrollment . No prior chemotherapy immunotherapy ( tumor vaccine , cytokine , growth factor give control prostate cancer ) . Prior radiation therapy complete least 4 week prior enrollment . No prior radiopharmaceutical ( strontium , samarium ) within 8 week prior enrollment . Bone pain due metastatic bone disease severe enough require routine narcotic analgesic use . History severe hypersensitivity reaction drug formulate polysorbate 80 . Patients active autoimmune disease history autoimmune disease require systemic steroid immunosuppressive medication , except patient vitiligo . Prior therapy anticytotoxic Tlymphocyte antigen 4 ( antiCTLA4 ) antibody . Active infection require therapy . Concurrent medical condition require use systemic topical corticosteroid ; systemic topical corticosteroid must discontinue least 4 week prior enrollment . The use inhale corticosteroid acceptable .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Oncology</keyword>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Hormone</keyword>
	<keyword>PSA</keyword>
	<keyword>Metastatic Hormone-Refractory Prostate Cancer ( HRPC )</keyword>
</DOC>